{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:38:19Z","timestamp":1783784299497,"version":"3.55.0"},"reference-count":86,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:p>The increasing availability of biologic therapies for allergic diseases has highlighted the need for more precise, mechanism-based patient selection. Traditional approaches based on disease phenotypes often fall short in predicting therapeutic response. Escalating healthcare costs together with questions about the efficacy of the current management of allergic diseases prompt to a shift toward endotype-driven and biomarker-guided strategies. This review explores the role of endotypes, defined by distinct immunologic, molecular, or cellular mechanisms, in guiding the use of targeted biologics in asthma and in chronic rhinosinusitis with nasal polyps. Endotype classification based on the type 1, type 2 and type 3 immune response is critical for selecting biologics targeting the IgE, IL-5, IL-4\/IL-13, or TSLP pathways. The endotype-driven approach in allergic diseases has tremendous potential if incorporated into comprehensive care pathways, with endotype identification playing a key role in the management decision tree, with improved outcomes and greater patient satisfaction. To this purpose this review provides decision algorithms for the endotype-guided approach at the point of care and discusses the unmet needs with potential practical solutions to support a personalized precision approach.<\/jats:p>","DOI":"10.3389\/falgy.2025.1754173","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:43:57Z","timestamp":1768196637000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Endotype-driven decisions in choosing a biologic for airway diseases"],"prefix":"10.3389","volume":"6","author":[{"given":"Carmen","family":"Panaitescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Haidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Roxana","family":"Buzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u0103zvan-Ionu\u021b","family":"Zimbru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin-Cristian","family":"Iovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena-Larisa","family":"Zimbru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"L\u0103culiceanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Agache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/B978-0-12-374419-7.00011-1","article-title":"Pathology: the clinical description of human disease","author":"Funkhouser","year":"2009","journal-title":"Mol Pathol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/all.15074","article-title":"Endotypes of chronic rhinosinusitis: relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches","volume":"77","author":"Kato","year":"2022","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41390-020-01231-6","article-title":"Defining pediatric asthma: phenotypes to endotypes and beyond","volume":"90","author":"Conrad","year":"2021","journal-title":"Pediatr Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1172\/JCI124611","article-title":"Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases","volume":"129","author":"Agache","year":"2019","journal-title":"J Clin Invest"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1361891","DOI":"10.3389\/fimmu.2024.1361891","article-title":"Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma","volume":"15","author":"Porsbjerg","year":"2024","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00005-018-0526-6","article-title":"Precision\/personalized medicine in allergic diseases and asthma","volume":"66","author":"Kucuksezer","year":"2018","journal-title":"Arch Immunol Ther Exp"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1111\/all.15889","article-title":"Nomenclature of allergic diseases and hypersensitivity reactions: adapted to modern needs: an EAACI position paper","volume":"78","author":"Jutel","year":"2023","journal-title":"Allergy"},{"key":"B9","first-page":"1","volume-title":"Global Atlas of Asthma","author":"Agache","year":"2021"},{"key":"B10","article-title":"GINA-Strategy-Report_2025-WEB-WMS.pdf","year":""},{"key":"B11","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1042\/CS20160253","article-title":"Pathogenesis of asthma: implications for precision medicine","volume":"131","author":"Russell","year":"2017","journal-title":"Clin Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jaci.2025.03.025","article-title":"Personalized therapeutic approaches for asthma","volume":"156","author":"Agache","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.alit.2016.04.011","article-title":"Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine","volume":"65","author":"Agache","year":"2016","journal-title":"Allergol Int"},{"key":"B14","first-page":"45","volume-title":"Endotype-driven Approach for Asthma. Implementing Precision Medicine in Best Practices of Chronic Airway Diseases","author":"Agache","year":"2019"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jaci.2024.07.024","article-title":"IL-2 family cytokines IL-9 and IL-21 differentially regulate innate and adaptive type 2 immunity in asthma","volume":"154","author":"Bick","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jaip.2019.11.020","article-title":"Diagnosis and management of T2-high asthma","volume":"8","author":"Coverstone","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","article-title":"The basic immunology of asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e70018","DOI":"10.1111\/imr.70018","article-title":"Pathobiology and regulation of eosinophils, mast cells, and basophils in allergic asthma","volume":"331","author":"Whetstone","year":"2025","journal-title":"Immunol Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3390\/biomedicines11041226","article-title":"T2-low asthma: a discussed but still orphan disease","volume":"11","author":"Peri","year":"2023","journal-title":"Biomedicines"},{"key":"B20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/all.13985","article-title":"Mechanisms and therapeutic strategies for non-T2 asthma","volume":"75","author":"Sze","year":"2020","journal-title":"Allergy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s41030-019-00109-1","article-title":"Severe asthma and biological therapy: when, which, and for whom","volume":"6","author":"Rogliani","year":"2020","journal-title":"Pulm Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3390\/jpm12040593","article-title":"Specific therapy for T2 asthma","volume":"12","author":"Bagnasco","year":"2022","journal-title":"J Pers Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4168\/aair.2020.12.1.24","article-title":"Critical points on the use of biologicals in allergic diseases and asthma","volume":"12","author":"Agache","year":"2020","journal-title":"Allergy Asthma Immunol Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jaip.2020.07.048","article-title":"Multidimensional assessment of asthma identifies clinically relevant phenotype overlap: a cross-sectional study","volume":"9","author":"Han","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2102669","DOI":"10.1183\/13993003.02669-2021","article-title":"The quest for biomarkers in asthma: challenging the T2 versus non-T2 paradigm","volume":"59","author":"Seys","year":"2022","journal-title":"Eur Respir J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jaci.2009.10.012","article-title":"Identification of a novel subset of human circulating memory CD4+ T cells that produce both IL-17A and IL-4","volume":"125","author":"Cosmi","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.jaci.2014.05.038","article-title":"Increased frequency of dual-positive TH2\/TH17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma","volume":"134","author":"Irvin","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3390\/jpm12071093","article-title":"Eosinophilic asthma, phenotypes-endotypes and current biomarkers of choice","volume":"12","author":"Porpodis","year":"2022","journal-title":"JPM"},{"key":"B30","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.chest.2024.06.3790","article-title":"Rethinking blood eosinophils for assessing inhaled corticosteroids response in COPD","volume":"166","author":"Mathioudakis","year":"2024","journal-title":"Chest"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.4103\/jfmpc.jfmpc_487_23","article-title":"Determination of sputum eosinophil count and serum absolute eosinophil count in patients with bronchial asthma and its correlation with disease severity and response to treatment","volume":"12","author":"Mangattu Parambil","year":"2023","journal-title":"J Family Med Prim Care"},{"key":"B32","doi-asserted-by":"publisher","first-page":"22476","DOI":"10.1038\/s41598-022-26949-7","article-title":"A sputum bioassay for airway eosinophilia using an eosinophil peroxidase aptamer","volume":"12","author":"Ali","year":"2022","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/all.16322","article-title":"Up-dosing of reslizumab in severe asthmatics with persistent sputum eosinophilia: a feasibility study","volume":"80","author":"Mukherjee","year":"2025","journal-title":"Allergy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.3390\/cells12212518","article-title":"Exhaled nitric oxide as biomarker of type 2 diseases","volume":"12","author":"Maniscalco","year":"2023","journal-title":"Cells"},{"key":"B35","doi-asserted-by":"publisher","first-page":"20406223231190480","DOI":"10.1177\/20406223231190480","article-title":"Fractional nitric oxide measurement in exhaled air (FeNO): perspectives in the management of respiratory diseases","volume":"14","author":"Ragnoli","year":"2023","journal-title":"Ther Adv Chronic Dis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13223-018-0312-3","article-title":"Serum periostin levels in adults of Chinese descent: an observational study","volume":"14","author":"Tan","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/all.12906","article-title":"Serum IL -5 and IL -13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics","volume":"71","author":"Agache","year":"2016","journal-title":"Allergy"},{"key":"B38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.aller.2015.05.006","article-title":"The efficacy of single-high dose inhaled corticosteroid versus oral prednisone treatment on exhaled leukotriene and 8-isoprostane levels in mild to moderate asthmatic children with asthma exacerbation","volume":"44","author":"Keskin","year":"2016","journal-title":"Allergol Immunopathol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/pai.12566","article-title":"Genetic associations of the response to inhaled corticosteroids in children during an asthma exacerbation","volume":"27","author":"Keskin","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S2213-2600(18)30149-8","article-title":"Adrenal suppression with inhaled corticosteroids: the seed and the soil\u2013Authors\u2019 reply","volume":"6","author":"Hawcutt","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S2213-2600(18)30058-4","article-title":"Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study","volume":"6","author":"Hawcutt","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11882-015-0529-x","article-title":"The complex type 2 endotype in allergy and asthma: from laboratory to bedside","volume":"15","author":"Agache","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s40521-014-0014-0","article-title":"Endotype driven treatment of asthma: endotypes and asthma treatment","volume":"1","author":"Agache","year":"2014","journal-title":"Curr Treat Options Allergy"},{"key":"B44","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40291-021-00514-w","article-title":"Treatable mechanisms in asthma","volume":"25","author":"Cazzola","year":"2021","journal-title":"Mol Diagn Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"S0012-3692(25)05380-2","DOI":"10.1016\/j.chest.2025.08.042","article-title":"Biologic management in severe asthma for adults: an American college of chest physicians clinical practice guideline","author":"Oberle","year":"2025","journal-title":"Chest"},{"key":"B46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EAACI biologicals guidelines\u2014recommendations for severe asthma","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"B47","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical response and remission in patients with severe asthma treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"key":"B48","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/jcm9030706","article-title":"Physical activity: a missing link in asthma care","volume":"9","author":"Panagiotou","year":"2020","journal-title":"J Clin Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/all.14256","article-title":"The evolving algorithm of biological selection in severe asthma","volume":"75","author":"Papadopoulos","year":"2020","journal-title":"Allergy"},{"key":"B50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.anai.2024.09.023","article-title":"Identifying super-responders: a review of the road to asthma remission","volume":"134","author":"Mailhot-Larouche","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3390\/diagnostics13040715","article-title":"The diagnostic and prognostic role of biomarkers in chronic rhinosinusitis","volume":"13","author":"Seah","year":"2023","journal-title":"Diagnostics"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.3390\/diagnostics12102301","article-title":"Perspectives in therapy of chronic rhinosinusitis","volume":"12","author":"Brzost","year":"2022","journal-title":"Diagnostics"},{"key":"B53","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/all.16418","article-title":"Endotyping in chronic rhinosinusitis\u2014an EAACI task force report","volume":"80","author":"Toppila-Salmi","year":"2025","journal-title":"Allergy"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","author":"Fokkens","year":"2020","journal-title":"Rhin"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.3390\/biomedicines12112647","article-title":"Update on the biological and clinical relevance of mast cells in chronic rhinosinusitis with nasal polyps","volume":"12","author":"Locatello","year":"2024","journal-title":"Biomedicines"},{"key":"B56","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jaci.2022.10.010","article-title":"Endotypes of chronic rhinosinusitis based on inflammatory and remodeling factors","volume":"151","author":"Wang","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3390\/biomedicines13020501","article-title":"Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma\u2014a multidisciplinary monocentric real-life study","volume":"13","author":"Fadda","year":"2025","journal-title":"Biomedicines"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.jaci.2017.09.009","article-title":"Chronic rhinosinusitis in Asia","volume":"140","author":"Zhang","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3390\/diagnostics12102361","article-title":"Immunological aspects of chronic rhinosinusitis","volume":"12","author":"Czerwaty","year":"2022","journal-title":"Diagnostics"},{"key":"B60","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/ijms22020910","article-title":"Advances in the knowledge of the underlying airway remodeling mechanisms in chronic rhinosinusitis based on the endotypes: a review","volume":"22","author":"Lee","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.anai.2018.10.014","article-title":"Pathophysiologic mechanisms of chronic rhinosinusitis and their roles in emerging disease endotypes","volume":"122","author":"Cao","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.3390\/ijms24055015","article-title":"Treatment strategy of uncontrolled chronic rhinosinusitis with nasal polyps: a review of recent evidence","volume":"24","author":"Kim","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B63","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/1744666X.2023.2233700","article-title":"Pathophysiology and management of Staphylococcus aureus in nasal polyp disease","volume":"19","author":"Xu","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3390\/jpm13050707","article-title":"Endotypes of nasal polyps in children: a multidisciplinary approach","volume":"13","author":"Sitzia","year":"2023","journal-title":"J Pers Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1111\/all.14892","article-title":"Highlights in the advances of chronic rhinosinusitis","volume":"76","author":"Xu","year":"2021","journal-title":"Allergy"},{"key":"B66","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/JAA.S290424","article-title":"Burden of disease in chronic rhinosinusitis with nasal polyps","volume":"14","author":"Bachert","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e70095","DOI":"10.1002\/clt2.70095","article-title":"Characterization of chronic rhinosinusitis patients based on markers of type 2 inflammation: findings from the European CRS outcome registry (CHRINOSOR)","volume":"15","author":"Cavaliere","year":"2025","journal-title":"Clin Transl Allergy"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin19.410","article-title":"European Position paper on diagnostic tools in rhinology","volume":"57","author":"Rimmer","year":"2019","journal-title":"Rhinology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/alr.23018","article-title":"Periostin as a biomarker in chronic rhinosinusitis: a contemporary systematic review","volume":"12","author":"Danielides","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12865-022-00507-2","article-title":"Serum IL-5, POSTN and IL-33 levels in chronic rhinosinusitis with nasal polyposis correlate with clinical severity","volume":"23","author":"Zieli\u0144ska-Bli\u017aniewska","year":"2022","journal-title":"BMC Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.anai.2024.05.023","article-title":"Factors for predicting the outcome of surgery for non-eosinophilic chronic rhinosinusitis with nasal polyps","volume":"133","author":"Li","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1159\/000532067","article-title":"A decade of pathogenesis advances in non-type 2 inflammatory endotypes in chronic rhinosinusitis: 2012\u20132022","volume":"184","author":"Cui","year":"2023","journal-title":"Int Arch Allergy Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1111\/all.14809","article-title":"Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"B75","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/jpm14030297","article-title":"Long-term perspectives on chronic rhinosinusitis with nasal polyps: evaluating recurrence rates after functional endoscopic sinus surgery in the biologics era\u2014a 5-year follow-up study","volume":"14","author":"Cavaliere","year":"2024","journal-title":"J Pers Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40463-019-0350-y","article-title":"Clinically relevant phenotypes in chronic rhinosinusitis","volume":"48","author":"Grayson","year":"2019","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B78","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/1945892418807590","article-title":"Chronic rhinosinusitis\u2014could phenotyping or endotyping aid therapy?","volume":"33","author":"Bayar Muluk","year":"2019","journal-title":"Am J Rhinol Allergy"},{"key":"B79","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/S0140-6736(25)01248-6","article-title":"The clinical effectiveness of clarithromycin versus endoscopic sinus surgery for adults with chronic rhinosinusitis with and without nasal polyps (MACRO): a pragmatic, multicentre, three-arm, randomised, placebo-controlled phase 4 trial","volume":"406","author":"Philpott","year":"2025","journal-title":"Lancet"},{"key":"B80","doi-asserted-by":"publisher","first-page":"0","DOI":"10.4193\/Rhin23.415","article-title":"EPOS2020\/EUFOREA Expert opinion on defining disease states and therapeutic goals in CRSwNP","author":"Fokkens","year":"2024","journal-title":"Rhin"},{"key":"B81","doi-asserted-by":"publisher","first-page":"S2213-2198(25)01128-6","DOI":"10.1016\/j.jaip.2025.11.023","article-title":"Targeted treatment in asthma\u2014opportunities and challenges","author":"Agache","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B82","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S2213-2600(25)00037-2","article-title":"Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials","volume":"13","author":"Meulmeester","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"338","DOI":"10.2500\/aap.2018.39.4165","article-title":"Cost impact of monitoring exhaled nitric oxide in asthma management","volume":"39","author":"Arnold","year":"2018","journal-title":"Allergy Asthma Proc"},{"key":"B84","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.anai.2024.06.016","article-title":"The combination of allergen immunotherapy and biologics for inhalant allergies: exploring the synergy","volume":"134","author":"Olivieri","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jaci.2022.08.029","article-title":"Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial","volume":"151","author":"Corren","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.anai.2020.01.013","article-title":"Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis","volume":"124","author":"Staudacher","year":"2020","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1754173\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:43:59Z","timestamp":1768196639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1754173\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":86,"alternative-id":["10.3389\/falgy.2025.1754173"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1754173","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1754173"}}